The Potential Role of Dyslipidemia in COVID-19 Severity: an Umbrella Review of Systematic Reviews

Choi, Geun Joo; Kim, Hyun Min; Kang, Hyun

doi:10.12997/jla.2020.9.3.435

Cited by 64 publications

(71 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A causal link between cardiovascular disease and COVID-19 outcomes, including thrombotic complications, has been proposed previously (23)(24)(25) but how exactly such clinical events relate to platelet activation phenotypes is not clear. Thus, we first assessed CD62P expression, both basal and following TRAP stimulation, in hospitalized COVID-19 patients that exhibited clinically evident thrombosis.…”

Section: Resultsmentioning

confidence: 97%

Signaling through FcγRIIA and the C5a-C5aR pathway mediates platelet hyperactivation in COVID-19

Apostolidis

Sarkar

Giannini

et al. 2021

Preprint

View full text Add to dashboard Cite

Patients with COVID-19 present with a wide variety of clinical manifestations. Thromboembolic events constitute a significant cause of morbidity and mortality in patients infected with SARS-CoV-2. Severe COVID-19 has been associated with hyperinflammation and pre-existing cardiovascular disease. Platelets are important mediators and sensors of inflammation and are directly affected by cardiovascular stressors. In this report, we found that platelets from severely ill, hospitalized COVID-19 patients exhibit higher basal levels of activation measured by P-selectin surface expression, and have a poor functional reserve upon in vitro stimulation. Correlating clinical features to the ability of plasma from COVID-19 patients to stimulate control platelets identified ferritin as a pivotal clinical marker associated with platelet hyperactivation. The COVID-19 plasma-mediated effect on control platelets was highest for patients that subsequently developed inpatient thrombotic events. Proteomic analysis of plasma from COVID-19 patients identified key mediators of inflammation and cardiovascular disease that positively correlated with in vitro platelet activation. Mechanistically, blocking the signaling of the FcγRIIa-Syk and C5a-C5aR pathways on platelets, using antibody-mediated neutralization, IgG depletion or the Syk inhibitor fostamatinib, reversed this hyperactivity driven by COVID-19 plasma and prevented platelet aggregation in endothelial microfluidic chamber conditions, thus identifying these potentially actionable pathways as central for platelet activation and/or vascular complications in COVID-19 patients. In conclusion, we reveal a key role of platelet-mediated immunothrombosis in COVID-19 and identify distinct, clinically relevant, targetable signaling pathways that mediate this effect. These studies have implications for the role of platelet hyperactivation in complications associated with SARS-CoV-2 infection.

show abstract

Section: Resultsmentioning

confidence: 97%

Signaling through FcγRIIA and the C5a-C5aR pathway mediates platelet hyperactivation in COVID-19

Apostolidis

Sarkar

Giannini

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Several studies have described rapid changes in the lipid profile in response to COVID-19 and the progression of the disease 4 . Therefore, a major gap may exist between the presence of dyslipidaemia prior to viral infection and the time at which lipid disturbances were detected at the time of hospitalization.…”

Section: Discussionmentioning

confidence: 99%

“…High blood pressure and dysglycaemia are associated with a worse prognosis; however, although dyslipidaemia is one of the main cardiovascular risk factors, the association between baseline lipid levels and the prognosis has been less frequently studied. In this respect, a recent umbrella review of systematic reviews suggested that dyslipidaemia may play a role in the severity of SARS-CoV-2 infection 4 .…”

Section: Introductionmentioning

confidence: 99%

Low HDL and high triglycerides predict COVID-19 severity

Masana

Correig

Ibarretxe

et al. 2021

Sci Rep

148

122

View full text Add to dashboard Cite

Lipids are indispensable in the SARS-CoV-2 infection process. The clinical significance of plasma lipid profile during COVID-19 has not been rigorously evaluated. We aim to ascertain the association of the plasma lipid profile with SARS-CoV-2 infection clinical evolution. Observational cross-sectional study including 1411 hospitalized patients with COVID-19 and an available standard lipid profile prior (n: 1305) or during hospitalization (n: 297). The usefulness of serum total, LDL, non-HDL and HDL cholesterol to predict the COVID-19 prognosis (severe vs mild) was analysed. Patients with severe COVID-19 evolution had lower HDL cholesterol and higher triglyceride levels before the infection. The lipid profile measured during hospitalization also showed that a severe outcome was associated with lower HDL cholesterol levels and higher triglycerides. HDL cholesterol and triglyceride concentrations were correlated with ferritin and D-dimer levels but not with CRP levels. The presence of atherogenic dyslipidaemia during the infection was strongly and independently associated with a worse COVID-19 infection prognosis. The low HDL cholesterol and high triglyceride concentrations measured before or during hospitalization are strong predictors of a severe course of the disease. The lipid profile should be considered as a sensitive marker of inflammation and should be measured in patients with COVID-19.

show abstract

“…This study was performed on patients who have not yet received treatment for Covid-19 disease. Previous studies suggested dyslipidemia in viral infections [12,13] and COVID-19 as well [14,15]. Various studies have been performed on the role of cholesterol in pulmonary function.…”

Section: Discussionmentioning

confidence: 99%

A Case-Control Study on Blood Lipid Profile in Patients with COVID-19

Changaripour

Sarvazad

Barghi

et al. 2021

Preprint

View full text Add to dashboard Cite

Background Dyslipidemia has been reported in patients with virus infections. This study was performed to evaluate the blood lipid profile in the patients with coronavirus disease 2019 (COVID-19), and exploring the underlying factors in its development and their predictive value for the severity of COVID-19.Methods In a case-control study, the lipid profile of patients with COVID-19 at the first admitted to two clinical centers in the west of Iran (July 2020 to Dec. 2020) and age- and gender-matched healthy people were explored. Three groups of controls, patients with the severe form of Covid-19 (admitted to the intensive care unit (ICU)), patients with Covid-19 with less intensity (outpatient admission), were defined for the subjects included in the study. The predictive values of different variables obtained from medical records for COVID-19 severity were analyzed.Results Generally, 48 outpatients and 49 ICU patients, including 70 men and 23 women with a mean age of 62.4±13.5 years, were included in the study. The control group consisted of 32 people, match sex and age with the patient groups. The mean triglyceride (TG) in the Covid-19 groups was higher than the control group, but there was no significant difference between them. The mean cholesterol in the patient groups was lower than the control group (p=0.001). The mean of low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) was significantly different in the patient groups; HDL-C in the ICU group was more than outpatient, and LDL-C in the outpatient group was more than ICU (P<0.05). LDL-C and HDL-C in the ICU group were less than the control group, but there was no statistically significant difference between the two mentioned groups. The frequency of diabetes and hypertension was higher in the ICU group than in the outpatient group (P<0.001). Furthermore, LDL-C level was associated with disease severity (odds ratio (OR): 0.966, 95% confidence interval (CI): 0.944-0.989, P= 0.004).Conclusion Lipid profiles in Covid-19 patients have different faces from healthy individuals. In the severe form, the lipid status has a different profile from the less severe form of Covid-19 disease. LDL-C level can be used as an indicator to determine the severity of Covid-19 disease.

show abstract

The Potential Role of Dyslipidemia in COVID-19 Severity: an Umbrella Review of Systematic Reviews

Cited by 64 publications

References 67 publications

Signaling through FcγRIIA and the C5a-C5aR pathway mediates platelet hyperactivation in COVID-19

Signaling through FcγRIIA and the C5a-C5aR pathway mediates platelet hyperactivation in COVID-19

Low HDL and high triglycerides predict COVID-19 severity

A Case-Control Study on Blood Lipid Profile in Patients with COVID-19

Contact Info

Product

Resources

About